Fluphenazine vs Placebo Supplementation for Prodromal Signs of Relapse in Schizophrenia
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We studied the effectiveness of treating patients with low doses of fluphenazine decanoate and supplementing them with oral fluphenazine when there was evidence of prodromal symptoms of psychotic exacerbations. METHODS: Eighty schizophrenic patients who were receiving 5 to 10 mg of fluphenazine decanoate every 2 weeks were monitored for prodromal symptoms using an idiosyncratic prodromal rating scale. When patients met our criteria for a prodromal episode, they were randomly assigned to a double-blind comparison of oral fluphenazine hydrochloride (5 mg twice daily) or a placebo for the current and future prodromal episodes. We compared rates of psychotic exacerbations in the two treatment groups. RESULTS: Thirty-six patients (45%) met the criteria for a prodrome at some point during the trial and were randomized to drug or placebo. Using survival analysis during the entire 2 years, we did not find a significant difference between fluphenazine and placebo in the likelihood that a prodrome would continue to an exacerbation. Survival analysis beginning at the start of the second year of treatment did indicate a significant reduction in exacerbation risk for patients receiving drug supplementation (P = .032). Similarly, there was no difference between the two groups in the proportion of time at risk spent in exacerbation during the first year, but patients receiving active drug supplementation spent less time in an exacerbated state in the second year (P = .05). CONCLUSIONS: Our treatment strategy appeared to be effective for some patients, particularly those who were able to remain in the study beyond the first year. Although the occurrence of a prodrome was a fairly good marker that a patient was at high risk of ultimate exacerbation with our low-dose maintenance protocol, prodromes were not highly sensitive indicators of imminent exacerbation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Birchwood, M., Smith, J., Macmillan, F., Hogg, B., Prasad, R., Harvey, C., & Bering, S. (1989) · Psychological Medicine · doi:10.1017/s0033291700024247 · Cited by 334
Cited by
Monitoring and Care of Young People at Incipient Risk of Psychosis
Yung, A. R., McGorry, P. D., McFarlane, C. A., Jackson, H. J., Patton, G. C., & Rakkar, A. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.2.283 · Cited by 772
A Program for Relapse Prevention in Schizophrenia: A Controlled Study
Herz, M. I., Lamberti, J. S., Mintz, J., Scott, R., O'Dell, S. P., McCartan, L., & Nix, G. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.277 · Cited by 260
Staging of Mental Disorders: Systematic Review
Cosci, F., & Fava, G. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000342243 · Cited by 235
GUMLEY, A., O'GRADY, M., MCNAY, L., REILLY, J., POWER, K., & NORRIE, J. (2003) · Psychological Medicine · doi:10.1017/s0033291703007323 · Cited by 229
“Eight prospective studies of early signs (Subotnik & Neuchterlein, 1988; Birchwood et al. 1989; Jolley et al. 1990; Marder et al. 1991, 1994; Tarrier et al. 1991; Gaebel et al. 1993; Jorgensen, 1998) confirm that relapse is almost always preceded by non-psychotic symptoms such as anxiety and…”
BackgroundFear of recurrence: Results of a randomized trial of relapse detection in schizophrenia
Gumley, A. I., MacBeth, A., Reilly, J. D., O'Grady, M., White, R. G., McLeod, H., Schwannauer, M., & Power, K. G. (2015) · British Journal of Clinical Psychology · doi:10.1111/bjc.12060 · Cited by 46
Metadata
- Authors
- Marder, S. R.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1994-04-01
- Volume
- 51
- Issue
- 4
- Pages
- 280
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W1964880741
- Cited by
- 81
- References
- 1
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fluphenazine vs Placebo Supplementation for Prodromal Signs of Relapse in Schizophrenia. https://app.cochat.ai/papers/10.1001/archpsyc.1994.03950040024003
- The paper
- Marder, S. R. (1994). Fluphenazine vs Placebo Supplementation for Prodromal Signs of Relapse in Schizophrenia. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1994.03950040024003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.